Valess

Vaxess Technologies is a venture-backed biotechnology company focused on transforming the delivery of vaccines and complex therapeutics through its proprietary MIMIX smart-release patch platform. Utilizing a silk-derived protein technology originally developed at Tufts University and MIT, the company's microarray patches enable sustained release of treatments ranging from minutes to months in a shelf-stable, needle-free format. Vaxess is currently advancing a diverse pipeline that includes programs for seasonal and pandemic influenza, COVID-19, and oncology, as well as next-generation delivery of GLP-1 receptor agonists for metabolic diseases. The company's technology aims to improve patient compliance and global access by eliminating the need for cold-chain distribution and professional administration.